Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 76
6.304,88 S&P · 19,03 Vola-Index · 117.428,21 BTC · 1,16280 EURUSD
System-State: Number of processed items 51.990 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US58933Y1055
State: 21.07.2025 | 12AM
Do you already know our new terminal view? Click here.
FIGI: BBG000BPD168
MRK
Merck & Company, Inc.
GICS: 35202010 · Sector: Healthcare · Sub-Sector: Drug Manufacturers—General
NAME
Merck & Company, Inc.
ISIN
US58933Y1055
TICKER
MRK
MIC
XNYS
REUTERS
MRK.N
BLOOMBERG
MRK US
Mon, 14.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) for HIV pre-exposure prophylaxis (PrEP). The EXPrESS...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.07.2025       Merck & Co.
US58933Y1055

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly1 injectable product to tre...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Wed, 09.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per Am...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) taking place July 13-17, 2025, in Kigali, Rwanda. Merck will share new scientific findings...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Wed, 02.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercep...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Tue, 01.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists an...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 26.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend ENFLONSIA™ (clesrovimab-cfor) as an option for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease ...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Tue, 24.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that scientific and commercial team leaders will host a virtual investor event where they will give an overview of the company’s advancing HIV treatment and prevention research pipeline on July 17, 2025, at 9:00 a.m. ET. Investors, analysts, members of the m...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Mon, 23.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional clas...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Wed, 18.06.2025       Merck & Co.
US58933Y1055

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor. Ifina...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Fri, 13.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (C...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 12.06.2025       Merck & Co.
US58933Y1055

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs. NUMELVI, a onc...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 12.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes ...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Mon, 09.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV se...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Mon, 09.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment ...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference o...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Sat, 31.05.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% (HR=0.65, p<0.001) versus KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ (Combined Positive S...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Fri, 30.05.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study, a clinical trial evaluating MK-1084, an investigational next-generation KRAS G12C inhibitor, alone and in combination with other therapies in certain patients with KRAS G12C-mutant so...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Fri, 30.05.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study evaluating zilovertamab vedotin in combination with standard of care rituximab and gemcitabine-oxaliplatin (R-GemOx) for the treatment of relapsed or refractory diffuse large B-cell...
Read More
Merck & Co.
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
China Dev Bank Fin Leasing Co Ltd
CDB Aviation and Loong Air Execute Lease Agreements for Six A321neo Aircraft
© BusinessWire
CAVA Group
CAVA’s First Ever Michigan Restaurant Opens in Canton
© BusinessWire
Edgewise Therapeutics
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
© BusinessWire
Altimmune
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
© BusinessWire
Unicycive Therapeutics
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
© BusinessWire
WPP
WPP Investors Have Opportunity to Join WPP plc Fraud Investigation with the Schall Law Firm
© BusinessWire
Sarepta Therapeutics
Sarepta Therapeutics Provides Statement on ELEVIDYS
© BusinessWire
Century Aluminum
CENTURY ALUMINUM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Century Aluminum Co. - CENX
© BusinessWire
Inspirato
INSPIRATO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inspirato Inc. - ISPO
© BusinessWire
Four Corners Property Trust
FCPT Announces Acquisition of Six Novant Health Urgent Care Properties for $12.0 Million
© BusinessWire
Block
Block Set to Join the S&P 500
© BusinessWire
GoodRx
GOODRX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GoodRx Holdings, Inc. - GDRX
© BusinessWire
Chewy
CHEWY INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Chewy, Inc. - CHWY
© BusinessWire
Capital One Financial
CAPITAL ONE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Capital One Financial Corporation - COF
© BusinessWire
Altice USA
ALTICE USA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Altice USA, Inc. - ATUS
© BusinessWire
Organon & Co.
ORGANON 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Organon & Co. - OGN
© BusinessWire
Red Cat
RED CAT 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Red Cat Holdings, Inc. - RCAT
© BusinessWire
Smith Micro Software
 Smith Micro Announces Closing of Follow-On Offering
© BusinessWire
New Germany Fund Inc
The New Germany Fund, Inc. Announces Results of the Fund’s Annual Meeting of Stockholders
© BusinessWire
Neogen
Grant & Eisenhofer Files Class Action Lawsuit Against Neogen Corporation
© BusinessWire
KB Home
KB Home Announces the Grand Opening of Its Newest Community in Highly Desirable Bothell, Washington
© BusinessWire
Delek Logistics
Delek Logistics Partners, LP to Host Second Quarter 2025 Conference Call on August 6th
© BusinessWire
Marcus Corp.
Marcus Corporation Announces Second Quarter Fiscal 2025 Release Date and Conference Call
© BusinessWire
Delek US
Delek US Holdings to Host Second Quarter 2025 Conference Call on August 6th
© BusinessWire
Mesa Royalty Trust
Mesa Royalty Trust Announces Trust Income for July 2025
© BusinessWire

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.

 

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S